Dexmedetomidine - An emerging option for sedation in neonatal patients
- PMID: 35197548
- DOI: 10.1038/s41372-022-01351-3
Dexmedetomidine - An emerging option for sedation in neonatal patients
Abstract
Dexmedetomidine is a sedative agent with limited dosing, safety, and efficacy information in the neonatal population. This comprehensive review describes the available evidence summarizing the use of dexmedetomidine in various neonatal populations. We identified 21 studies and 1 case report supporting the efficacy and short-term safety of DEX in neonates. Reported dosing ranges from 0.5-1.5 mcg/kg/h with or without loading doses. Clinically relevant adverse effects include bradycardia and hypotension. Future studies are needed to determine long-term safety and facilitate clinical applicability.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.
References
-
- Dexmedetomidine hydrochloride [package insert]. Parmaus (NJ): HQ Specialty Pharma Cooperation; 2015.
-
- Estkowski LM, Morris JL, Sinclair EA. Characterization of dexmedetomidine dosing and safety in neonates and infants. J Pediatr Pharm Ther. 2015;20:112–8.
-
- Ard J, Doyle W, Bekker A. Awake craniotomy with dexmedetomidine in pediatric patients. J Neurosurg Anesthesiol. 2003;15:263–6. - DOI
-
- Ni J, Wei J, Yao Y, Jiang X, Luo L, Luo D. Effect of dexmedetomidine on preventing postoperative agitation in children: a meta-analysis. PLoS One. 2015;10:e0128450. - DOI
-
- Tug A, Hanci A, Turk HS, Aybey F, Isil CT, Sayin P, et al. Comparison of two different intranasal doses of dexmedetomidine in children for magnetic resonance imaging sedation. Paediatr Drugs. 2015;17:479–85. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
